Analysis reveals LINC02802 enhances non-small cell lung cancer progression, indicating a critical role for mitochondrial metabolism and miR-1976 modulation.
Key Points
LINC02802 promotes non-small cell lung cancer progression by increasing mitochondrial NAD+/NADH ratio.
Elevated LINC02802 correlates with poor prognosis and miR-1976 suppression of SLC25A51 in NSCLC tissues.
Interventions targeting LINC02802 or SLC25A51 effectively reverse drug resistance in lung cancer models.
This study highlights a lncRNA-microRNA-metabolic pathway that may provide new therapeutic strategies for NSCLC.